Used primarily to protect the heart from damage caused by certain chemotherapy drugs, particularly doxorubicin. It is administered in cancer patients, especially those with advanced breast cancer, to reduce the risk of cardiotoxicity associated with high cumulative doses of anthracyclines. Dexrazoxane works by interfering with the formation of free radicals in heart tissue, which are responsible for oxidative damage. Its use allows for continued effective cancer treatment while preserving cardiac function. It is also utilized in the management of extravasation incidents involving anthracyclines, helping to minimize tissue damage when the drug leaks into surrounding tissues during infusion.